Skip to content
thispeptide

Ozempic Nausea: How Common It Is, When It Fades and What Helps

Nausea is the most reported side effect of semaglutide: 44% on Wegovy 2.4 mg against 16% on placebo, and up to 20.3% on Ozempic for diabetes. It clusters in the first weeks and after dose increases, and guidance starts with smaller, slower meals.

Article type
Safety
Sources
6
Reading
6 min
By Molly WardPublished

If you feel sick to your stomach on Ozempic, you are in large company.

Nausea is the side effect people report most on semaglutide. It is also the one that most often fades. Here is what the trials counted and what clinical guidance suggests. The wider list is in semaglutide side effects.

How common is it?

It depends on the dose and on why you take it. Ozempic is approved for type 2 diabetes. Wegovy is the same drug at higher doses for weight.

Nausea in placebo-controlled trials, from each drug's label
Drug, dose and populationDrug groupPlacebo
Ozempic 0.5 mg, type 2 diabetes15.8%6.1%
Ozempic 1 mg, type 2 diabetes20.3%6.1%
Wegovy 2.4 mg, weight trials44%16%
Wegovy 7.2 mg, weight trials39%13%
Zepbound (tirzepatide) 10 mg, weight trials29%8%
Nausea in placebo-controlled trials, from each drug's label

The Ozempic rows come from its label’s diabetes trials [1]. The Wegovy rows come from its weight trials [2]. In the 7.2 mg trials, the 2.4 mg arm reported nausea at 35%.

The tirzepatide row is from the Zepbound label [3]. These are separate trials, so the rows are not a head-to-head result.

When it starts and when it fades

Most reports of nausea, vomiting and diarrhea came during dose escalation, the Ozempic label says [1]. The Wegovy label says the same for its weight trials [2].

A multidisciplinary consensus paper puts numbers on it [4]. Nausea is most common in the first 4 to 5 weeks, when stomach emptying is slowed most. Symptoms are usually moderate and pass within 8 days of when they begin.

A pooled look at the STEP 1 to 3 weight trials found the same shape [5]. Nausea hit 43.9% on semaglutide 2.4 mg against 16.1% on placebo. Of all stomach and bowel events, 99.5% were not serious and 98.1% were mild to moderate.

Each step up in dose can bring it back for a while. The dose ladder is laid out in semaglutide dosage.

Does nausea mean the drug is working?

Not by the trial data. In STEP 1 to 3, weight loss was similar in people with and without stomach side effects [5].

A mediation analysis found these side effects explained less than 1 percentage point of the extra weight lost on semaglutide. By that analysis, feeling sick is not what drives the loss.

What the guidance suggests

The two papers below are expert guidance, not trials that tested each step. Both start with how you eat.

The 2025 nutrition advisory notes nausea often shows up in the morning or after long gaps without food [6]. It warns of a cycle: skipping food because of nausea makes the nausea worse.

It suggests a small breakfast, then small meals every 3 to 4 hours, with enough fluids. It adds that ginger or peppermint tea and acupressure bands can help.

The consensus paper lists eating slowly, smaller portions and stopping at the first sense of fullness [4]. It also suggests bland, low-fat food and not lying down right after a meal.

For nausea itself, it names crackers, apples, mint and ginger, and avoiding strong smells. Food choices are covered in more depth in what to eat on semaglutide.

The consensus paper sets a limit on that approach [4]. If you need anti-nausea drugs for more than a month at your maintenance dose, it says a dose reduction should be considered.

Alcohol can make it worse too. The advisory says drinking may worsen nausea and reflux on these drugs [6]. More is in Ozempic and alcohol.

When nausea is more than routine

Vomiting and poor intake can dry you out. The Wegovy label warns of kidney injury from fluid loss, and tells you to report nausea or vomiting that does not go away [2].

In the weight trials, 1.8% on Wegovy 2.4 mg stopped treatment because of nausea, against 0.2% on placebo.

The Ozempic label lists pancreatitis as a warning [1]. Signs may include persistent or severe belly pain, sometimes spreading to the back, with or without vomiting.

Other side effects in this group are covered in tirzepatide diarrhea and semaglutide headache.

To compare prescribers, see the compounded semaglutide rankings.

Frequently asked questions

How common is nausea on Ozempic?
In the Ozempic label's diabetes trials, nausea was reported by 15.8% on 0.5 mg and 20.3% on 1 mg, against 6.1% on placebo. At the higher Wegovy 2.4 mg dose for weight, it was 44% against 16%.
How long does semaglutide nausea last?
A consensus paper on GLP-1 side effects reports nausea is most common in the first 4 to 5 weeks, and that symptoms usually pass within 8 days of when they begin. It can return briefly after each dose increase.
Does nausea mean semaglutide is working?
No. In the pooled STEP 1 to 3 trials, weight loss was similar with and without stomach side effects, and those side effects explained less than 1 percentage point of the extra weight lost.
Does tirzepatide cause less nausea?
In the Zepbound label's weight trials, nausea was reported by 25% to 29% across doses, against 8% on placebo. The Wegovy 2.4 mg figure was 44%, but these are separate trials, not a head-to-head comparison.

Sources

6 cited
  1. 1DailyMed, U.S. National Library of Medicine (2026). OZEMPIC (semaglutide) injection, for subcutaneous use: prescribing information (DailyMed version effective 06/2026) DailyMed. Source
  2. 2DailyMed, U.S. National Library of Medicine (2026). WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets: prescribing information (revised 06/2026) DailyMed. Source
  3. 3DailyMed, U.S. National Library of Medicine (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information (revised 08/2026) DailyMed. Source
  4. 4Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, et al. (2022). Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus Journal of Clinical Medicine. PMID 36614945
  5. 5Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss Diabetes, Obesity and Metabolism. PMID 34514682
  6. 6Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society American Journal of Clinical Nutrition. PMID 40450457

More on weight